MYD88 and diffuse large B-cell lymphoma: We performed a comparative analysis of genomic alterations detected in PCL versus Systemic DLBCL and found significant enrichment for genomic alterations (GAs) in the following genes: MYD88 (58.0% vs 15.5%, P < .001), CDKN2A (47.8% vs 26.4% P ≤ .002), CD79B (29.0% vs 6.2%, P < .001), ETV6 (18.8% vs 4.3%, P < .001), PRDM1 (20.3% vs 4.2%, P < .001), PIM1 (18.8% vs 7.0%, P ≤ .010), and CXCR4 (8.7% vs 2.0%, P ≤ .019).